Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP
Summary Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the cor...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2020-03, Vol.188 (6), p.860-871 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 871 |
|---|---|
| container_issue | 6 |
| container_start_page | 860 |
| container_title | British journal of haematology |
| container_volume | 188 |
| creator | Jeon, Young‐Woo O, Joo‐Hyun Park, Kyung‐Sin Min, Gi June Park, Sung‐Soo Yoon, Jae‐Ho Eom, Ki‐Seong Min, Chang‐Ki Cho, Seok‐Goo |
| description | Summary
Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end‐of‐treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five‐year overall survival (OS) [hazard ratio (HR) 7·84, P |
| doi_str_mv | 10.1111/bjh.16257 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7155042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2315104339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4437-7e58a9e9f39408c720ed026c1bf16e7d7fad5dca33a11359d5bfe516387a1dc93</originalsourceid><addsrcrecordid>eNp1kcFuEzEURS0EomlgwQ8gS2zoYlq_8Xic2SBBBARUqRWCteV43mQczdiD7VCFFZ_AN_IlOKRUgIQ3tvSOru99l5AnwM4hn4v1tj-HuhTyHpkBr0VRQgX3yYwxJgtg1eKEnMa4ZQw4E_CQnHCQnEMpZuTrdfAb52Oyhtpx0iZR31HrEgY70slHm4J3FEcbo82P5Ee_CXrq9xmio3ZpQGpwGOiwH6fej5pOOll0KdIUUCds6Y1NPe2yTBqsQ_rhx7fvy9XV9SPyoNNDxMe395x8evP643JVXF69fbd8eVmYquKykCgWusGm403FFkaWDFtW1gbWHdQoW9npVrRGc64BuGhase5QQM0XUkNrGj4nL4660249Ymuyt6AHNeWAOuyV11b9PXG2Vxv_RUkQglVlFnh-KxD85x3GpPI2Dpm1Q7-LquQg8pY5P_z17B9063fB5XiZknXFapG5OTk7Uib4GAN2d2aAqUOjKjeqfjWa2ad_ur8jf1eYgYsjcGMH3P9fSb16vzpK_gR9rK5A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2376406543</pqid></control><display><type>article</type><title>Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP</title><source>Wiley Journals</source><source>Wiley Online Library Free Content</source><creator>Jeon, Young‐Woo ; O, Joo‐Hyun ; Park, Kyung‐Sin ; Min, Gi June ; Park, Sung‐Soo ; Yoon, Jae‐Ho ; Eom, Ki‐Seong ; Min, Chang‐Ki ; Cho, Seok‐Goo</creator><creatorcontrib>Jeon, Young‐Woo ; O, Joo‐Hyun ; Park, Kyung‐Sin ; Min, Gi June ; Park, Sung‐Soo ; Yoon, Jae‐Ho ; Eom, Ki‐Seong ; Min, Chang‐Ki ; Cho, Seok‐Goo</creatorcontrib><description>Summary
Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end‐of‐treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five‐year overall survival (OS) [hazard ratio (HR) 7·84, P < 0·0001] and poor five‐year progression‐free survival (PFS) (HR 3·34, P < 0·0001). OS and PFS were more favourable in the order early metabolic responder (iPETneg → ePETneg), delayed responder (iPETpos → ePETneg), loss‐metabolic responder (iPETneg → ePETpos), and never‐metabolic responder (iPETpos → ePETpos). In the autologous haematopoietic stem cell transplantation (auto‐HSCT)‐fit subgroup, OS was more favourable in the order early metabolic responders, delayed metabolic responders, and non‐metabolic responders, with a marginal trend toward statistical significance (HR 3·41, P = 0·051), and PFS was significantly superior in early metabolic responders (HR 4·43, P = 0·002). In a group that was ineligible for auto‐HSCT, OS and PFS were significantly superior in early metabolic responders. Our results suggested that iPET is of prognostic value and an independent predictor of survival in MCL patients receiving frontline R‐CHOP. Therefore, prospective clinical trials of iPET‐guided treatment strategies for these patients are warranted.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.16257</identifier><identifier>PMID: 31733125</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Autografts ; Clinical trials ; Cyclophosphamide ; Doxorubicin ; Haematological Malignancy – Clinical ; Hematology ; Hematopoietic stem cells ; interim 18F‐FDG PET ; Lymphoma ; Mantle cell lymphoma ; Metabolism ; Monoclonal antibodies ; Patients ; Positron emission tomography ; Prednisolone ; prognosis ; Research Paper ; Rituximab ; R‐CHOP ; Stem cell transplantation ; Targeted cancer therapy ; Tomography ; treatment response ; Vincristine</subject><ispartof>British journal of haematology, 2020-03, Vol.188 (6), p.860-871</ispartof><rights>2019 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd</rights><rights>2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4437-7e58a9e9f39408c720ed026c1bf16e7d7fad5dca33a11359d5bfe516387a1dc93</citedby><cites>FETCH-LOGICAL-c4437-7e58a9e9f39408c720ed026c1bf16e7d7fad5dca33a11359d5bfe516387a1dc93</cites><orcidid>0000-0003-3362-8200 ; 0000-0002-2145-9131 ; 0000-0002-8826-4136 ; 0000-0002-5429-4839</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.16257$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.16257$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31733125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeon, Young‐Woo</creatorcontrib><creatorcontrib>O, Joo‐Hyun</creatorcontrib><creatorcontrib>Park, Kyung‐Sin</creatorcontrib><creatorcontrib>Min, Gi June</creatorcontrib><creatorcontrib>Park, Sung‐Soo</creatorcontrib><creatorcontrib>Yoon, Jae‐Ho</creatorcontrib><creatorcontrib>Eom, Ki‐Seong</creatorcontrib><creatorcontrib>Min, Chang‐Ki</creatorcontrib><creatorcontrib>Cho, Seok‐Goo</creatorcontrib><title>Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end‐of‐treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five‐year overall survival (OS) [hazard ratio (HR) 7·84, P < 0·0001] and poor five‐year progression‐free survival (PFS) (HR 3·34, P < 0·0001). OS and PFS were more favourable in the order early metabolic responder (iPETneg → ePETneg), delayed responder (iPETpos → ePETneg), loss‐metabolic responder (iPETneg → ePETpos), and never‐metabolic responder (iPETpos → ePETpos). In the autologous haematopoietic stem cell transplantation (auto‐HSCT)‐fit subgroup, OS was more favourable in the order early metabolic responders, delayed metabolic responders, and non‐metabolic responders, with a marginal trend toward statistical significance (HR 3·41, P = 0·051), and PFS was significantly superior in early metabolic responders (HR 4·43, P = 0·002). In a group that was ineligible for auto‐HSCT, OS and PFS were significantly superior in early metabolic responders. Our results suggested that iPET is of prognostic value and an independent predictor of survival in MCL patients receiving frontline R‐CHOP. Therefore, prospective clinical trials of iPET‐guided treatment strategies for these patients are warranted.</description><subject>Autografts</subject><subject>Clinical trials</subject><subject>Cyclophosphamide</subject><subject>Doxorubicin</subject><subject>Haematological Malignancy – Clinical</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>interim 18F‐FDG PET</subject><subject>Lymphoma</subject><subject>Mantle cell lymphoma</subject><subject>Metabolism</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Prednisolone</subject><subject>prognosis</subject><subject>Research Paper</subject><subject>Rituximab</subject><subject>R‐CHOP</subject><subject>Stem cell transplantation</subject><subject>Targeted cancer therapy</subject><subject>Tomography</subject><subject>treatment response</subject><subject>Vincristine</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kcFuEzEURS0EomlgwQ8gS2zoYlq_8Xic2SBBBARUqRWCteV43mQczdiD7VCFFZ_AN_IlOKRUgIQ3tvSOru99l5AnwM4hn4v1tj-HuhTyHpkBr0VRQgX3yYwxJgtg1eKEnMa4ZQw4E_CQnHCQnEMpZuTrdfAb52Oyhtpx0iZR31HrEgY70slHm4J3FEcbo82P5Ee_CXrq9xmio3ZpQGpwGOiwH6fej5pOOll0KdIUUCds6Y1NPe2yTBqsQ_rhx7fvy9XV9SPyoNNDxMe395x8evP643JVXF69fbd8eVmYquKykCgWusGm403FFkaWDFtW1gbWHdQoW9npVrRGc64BuGhase5QQM0XUkNrGj4nL4660249Ymuyt6AHNeWAOuyV11b9PXG2Vxv_RUkQglVlFnh-KxD85x3GpPI2Dpm1Q7-LquQg8pY5P_z17B9063fB5XiZknXFapG5OTk7Uib4GAN2d2aAqUOjKjeqfjWa2ad_ur8jf1eYgYsjcGMH3P9fSb16vzpK_gR9rK5A</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Jeon, Young‐Woo</creator><creator>O, Joo‐Hyun</creator><creator>Park, Kyung‐Sin</creator><creator>Min, Gi June</creator><creator>Park, Sung‐Soo</creator><creator>Yoon, Jae‐Ho</creator><creator>Eom, Ki‐Seong</creator><creator>Min, Chang‐Ki</creator><creator>Cho, Seok‐Goo</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3362-8200</orcidid><orcidid>https://orcid.org/0000-0002-2145-9131</orcidid><orcidid>https://orcid.org/0000-0002-8826-4136</orcidid><orcidid>https://orcid.org/0000-0002-5429-4839</orcidid></search><sort><creationdate>202003</creationdate><title>Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP</title><author>Jeon, Young‐Woo ; O, Joo‐Hyun ; Park, Kyung‐Sin ; Min, Gi June ; Park, Sung‐Soo ; Yoon, Jae‐Ho ; Eom, Ki‐Seong ; Min, Chang‐Ki ; Cho, Seok‐Goo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4437-7e58a9e9f39408c720ed026c1bf16e7d7fad5dca33a11359d5bfe516387a1dc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Autografts</topic><topic>Clinical trials</topic><topic>Cyclophosphamide</topic><topic>Doxorubicin</topic><topic>Haematological Malignancy – Clinical</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>interim 18F‐FDG PET</topic><topic>Lymphoma</topic><topic>Mantle cell lymphoma</topic><topic>Metabolism</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Prednisolone</topic><topic>prognosis</topic><topic>Research Paper</topic><topic>Rituximab</topic><topic>R‐CHOP</topic><topic>Stem cell transplantation</topic><topic>Targeted cancer therapy</topic><topic>Tomography</topic><topic>treatment response</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeon, Young‐Woo</creatorcontrib><creatorcontrib>O, Joo‐Hyun</creatorcontrib><creatorcontrib>Park, Kyung‐Sin</creatorcontrib><creatorcontrib>Min, Gi June</creatorcontrib><creatorcontrib>Park, Sung‐Soo</creatorcontrib><creatorcontrib>Yoon, Jae‐Ho</creatorcontrib><creatorcontrib>Eom, Ki‐Seong</creatorcontrib><creatorcontrib>Min, Chang‐Ki</creatorcontrib><creatorcontrib>Cho, Seok‐Goo</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeon, Young‐Woo</au><au>O, Joo‐Hyun</au><au>Park, Kyung‐Sin</au><au>Min, Gi June</au><au>Park, Sung‐Soo</au><au>Yoon, Jae‐Ho</au><au>Eom, Ki‐Seong</au><au>Min, Chang‐Ki</au><au>Cho, Seok‐Goo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2020-03</date><risdate>2020</risdate><volume>188</volume><issue>6</issue><spage>860</spage><epage>871</epage><pages>860-871</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end‐of‐treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five‐year overall survival (OS) [hazard ratio (HR) 7·84, P < 0·0001] and poor five‐year progression‐free survival (PFS) (HR 3·34, P < 0·0001). OS and PFS were more favourable in the order early metabolic responder (iPETneg → ePETneg), delayed responder (iPETpos → ePETneg), loss‐metabolic responder (iPETneg → ePETpos), and never‐metabolic responder (iPETpos → ePETpos). In the autologous haematopoietic stem cell transplantation (auto‐HSCT)‐fit subgroup, OS was more favourable in the order early metabolic responders, delayed metabolic responders, and non‐metabolic responders, with a marginal trend toward statistical significance (HR 3·41, P = 0·051), and PFS was significantly superior in early metabolic responders (HR 4·43, P = 0·002). In a group that was ineligible for auto‐HSCT, OS and PFS were significantly superior in early metabolic responders. Our results suggested that iPET is of prognostic value and an independent predictor of survival in MCL patients receiving frontline R‐CHOP. Therefore, prospective clinical trials of iPET‐guided treatment strategies for these patients are warranted.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>31733125</pmid><doi>10.1111/bjh.16257</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3362-8200</orcidid><orcidid>https://orcid.org/0000-0002-2145-9131</orcidid><orcidid>https://orcid.org/0000-0002-8826-4136</orcidid><orcidid>https://orcid.org/0000-0002-5429-4839</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2020-03, Vol.188 (6), p.860-871 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7155042 |
| source | Wiley Journals; Wiley Online Library Free Content |
| subjects | Autografts Clinical trials Cyclophosphamide Doxorubicin Haematological Malignancy – Clinical Hematology Hematopoietic stem cells interim 18F‐FDG PET Lymphoma Mantle cell lymphoma Metabolism Monoclonal antibodies Patients Positron emission tomography Prednisolone prognosis Research Paper Rituximab R‐CHOP Stem cell transplantation Targeted cancer therapy Tomography treatment response Vincristine |
| title | Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A07%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20of%20interim%20positron%20emission%20tomography%20in%20mantle%20cell%20lymphoma%20patients%20treated%20with%20frontline%20R%E2%80%90CHOP&rft.jtitle=British%20journal%20of%20haematology&rft.au=Jeon,%20Young%E2%80%90Woo&rft.date=2020-03&rft.volume=188&rft.issue=6&rft.spage=860&rft.epage=871&rft.pages=860-871&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.16257&rft_dat=%3Cproquest_pubme%3E2315104339%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2376406543&rft_id=info:pmid/31733125&rfr_iscdi=true |